The relapsed/refractory multiple myeloma market landscape is undergoing a radical transformation with the recent FDA approvals of two CAR-Ts which is opening up new avenues for companies developing later lines of therapy. Several key players are racing to bring their candidates to the…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.